BioPharma, Pharma A Nonprofit Pharma Nabs FDA Nod for Nonprescription Naloxone Nasal Spray By Frank Vinluan
MedCity Influencers Will 2024 be the Year We Address the Real Roots of the Opioid Crisis? By Dr. Nishi Rawat
Daily, MedCity Influencers Increasing the Impact of Opioid Settlement Funds by Investing in Health IT Infrastructure By Kasey R. Claborn, Kat McDavitt, Katie A. McCormick, George Gooch and Nora Cox
BioPharma, Pharma FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine By Frank Vinluan
BioPharma, Pharma Regulatory Roundup: Narcan’s Nod, an ALS Adcomm, FDA Holds Lifted & More By Frank Vinluan
Health Tech New National Tracker for Non-fatal Overdoses Is ‘a Step in the Right Direction’ to End the Opioid Crisis By Katie Adams
Consumer / Employer OIG: Over 50,000 Medicare Part D beneficiaries experienced an opioid overdose in 2021 By Marissa Plescia
Daily A needle exchange project modeled on urban efforts aims to save lives in rural Nevada By Jazmin Orozco Rodriguez, Kaiser Health News
Hospitals, Health IT How providers are tackling a crisis within a crisis — the opioid epidemic By Anuja Vaidya
Policy Think ‘Medicare For All’ is the only Democratic health plan? Think Again By Emmarie Huetteman, Kaiser Health News
BioPharma, Legal Reckitt Benckiser to pay federal government $1.4B to resolve investigation into opioid sales By Alaric DeArment
Hospitals Northwell Health reveals program for emergency departments to help patients with opioid use disorder By Erin Dietsche
Kaiser Is Trump’s tough talk on pharma drug prices just a way to drive political contributions? By Sydney Lupkin and Elizabeth Lucas, Kaiser Health News